Attendee Testimonials

“The annual TPD Summit continues to be a must-attend event for those of us either working in or interested in the emerging field of targeted protein degraders. Most of the key players, from both academia and industry, gave presentations that covered many of the directions in which this rapidly evolving field is moving. The preconference workshop that I attended provided an in-depth discussion of the biochemical underpinnings of TPD and talks on emerging technologies like LYTACs and Craig Crews’ new TRAFTACs created a lot of excitement too. I was also please by the many follow-ups I received after the meeting to what was my company’s first public presentation on our technology. Although we missed the in-person interactions with the virtual format this year, the online meeting was very well organized, with numerous networking opportunities, and as a speaker and session chair I found it easy to participate. As always, having access to presentations after the meeting was over also greatly increases the value of the meeting by being able to review sessions that I couldn’t attend. I definitely plan on participating next year again”


"It was a well-organized virtual conference, and I am so glad to see both industry and academics are actively involved in the research of protein degradation"

download (1)

"Best virtual conference of this crazy COVID year"


"As in previous years, a fantastic and well-organized conference covering a variety of topics in the TPD field"


"This was the first virtual conference I participated in, and I admit it was a great experience overall"

download (2)

"It was a really well-run conference with many great speakers made it worth attending (even if only remotely)"


"It was a blast!!! Like a scientific rock festival"


"The virtual conference was intuitively organized and smoothly run"

Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

"The speaker line-up was top-notch while the flow of the virtual conference was simultaneously informal, professional, and highly interactive"


Speaker Testimonials

Tauseef Butt




“PROTAC approaches to develop antiviral drugs is a new strategy. The world has not overcome the SARS epidemic. It is likely that outbreak of highly transmissible and pathogenic virus will continue to devastate the world economies. PROTAC-based drugs have not been successful antiviral therapy thus far. This presentation will illustrate a promising PROTAC approach to irradicate SARS-CoV-2”

Beth Hoffman


Origami Therapeutics 


Beth Hoffman

“As the field of targeted protein degradation matures, it’s critical to have the best and brightest minds sharing experience and insights so that we can all deliver the best medicines for the patients and their families. The Hanson Wade Targeted Protein Degradation Conference is designed to do just that through speaker presentations and workshops”

David Millan

VP Chemistry

Foghorn Therapeutics


David Millan

“TPD is an excellent meeting to get an overview of the field and be exposed to all of the cutting-edge trends and approaches in targeted protein degradation.”

Kevin Foley


Ranok Therapeutics 




Kevin Foley

“This conference has become the “must attend” annual opportunity to interact with thought leaders in this exciting area”

Kate Jackson

Senior Director of Chemistry

C4 Therapeutics 





Kate Jackson

“In such a rapidly evolving field, it is nice to have a venue to check in on progress across companies.  This is an excellent forum to meet the key players in the field and absorb new advances.”

Markus Queisser

Scientific Director






Markus Queisser

“The Summit has developed as the most important event for our community where we annually discuss trends and advances in the TPD field”

Jennifer Venable

Senior Scientific Director, Discovery Chemistry

Janssen Research & Development 





Jennifer Venable

“The annual TPD summit meeting allows for exchanges with the critical minds across a vast cross-discipline field. Not only can you learn the latest developments but also identify future breakthroughs”

Sharon Townson


Monte Rosa Therapeutics 





Sharon Townson

“This is a great opportunity to get updated on new technologies, targets, and indications in the TPD space from leading experts in both academia and pharma.”

Kumar Suresh

Senior Director R&D

Progenra Inc 





Suresh Kumar

“Developing protein degrader drugs targeting neurodegenerative disease is the next biggest challenge. PROTACs will have limited application in the CNS disease space. Molecular glues that target specific E3 ligases is an attractive approach. This meeting is a fantastic platform that brings innovative ideas to tackle the challenges associated with developing protein degradation therapies”